Litcius/Paper detail

Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials

George J. Kahaly, Raymond S. Douglas, Robert J. Holt, Saba Sile, Terry J. Smith

2021The Lancet Diabetes & Endocrinology179 citationsDOI

Topics & Concepts

MedicineDiplopiaPlaceboGraves' ophthalmopathyThyroidGraves' diseaseRandomized controlled trialSurgeryPediatricsEye diseaseInternal medicinePathologyAlternative medicineOphthalmology and Eye DisordersGlaucoma and retinal disordersCerebral Venous Sinus Thrombosis
Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials | Litcius